News & Updates

Hydroxychloroquine protects SLE patients against CV events
Hydroxychloroquine protects SLE patients against CV events
11 Sep 2024

Among patients with systemic lupus erythematosus (SLE), those who use of hydroxychloroquine are less likely to experience cardiovascular events, as reported in a study.

Hydroxychloroquine protects SLE patients against CV events
11 Sep 2024
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
01 Sep 2024 byJairia Dela Cruz

In the treatment of patients with early oligoarticular psoriatic arthritis (PsA), the use of apremilast yields substantial improvements in both clinical and patient-reported outcomes, as shown in the results of the phase IV FOREMOST study.

Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
01 Sep 2024
Do children with JIA fare poorly in school?
Do children with JIA fare poorly in school?
01 Sep 2024

Children with juvenile idiopathic arthritis (JIA) show similar well-being and academic performance as those without JIA, according to a study.

Do children with JIA fare poorly in school?
01 Sep 2024
Tofacitinib safe, efficacious in ankylosing spondylitis regardless of baseline CRP
Tofacitinib safe, efficacious in ankylosing spondylitis regardless of baseline CRP
31 Aug 2024
RA disease activity, provider preference linked to telehealth appropriateness
RA disease activity, provider preference linked to telehealth appropriateness
30 Aug 2024
Circulating IL-17A predicts CVD in early RA
Circulating IL-17A predicts CVD in early RA
29 Aug 2024

Circulating interleukin (IL)-17A in patients diagnosed with rheumatoid arthritis (RA) is associated with the incidence of cardiovascular disease (CVD), independent of traditional CVD risk factors and of erythrocyte sedimentation rate (ESR) at the time of diagnosis, suggests a study.

Circulating IL-17A predicts CVD in early RA
29 Aug 2024